

Biosafety Issues and Strategy in the Western Pacific Region

Futoshi Hasebe

ADB-WHO Regional Outbreak Response Team

WHO Western Pacific Regional Office (WPRO)



Laboratory-Acquired SARS Outbreaks

- Singapore September 2003
- Taiwan (China) December 2003
- Beijing and Anhui (China) March 2004



Laboratory-Acquired Case of SARS

Singapore, September 2003

- Patient: 27-year-old graduate student
- Place of infection: BSL-3 lab., Environmental Health Institute
- Onset of illness: Aug. 26, 2003
- Hospitalization: Sept. 3, 2003
- Confirmed day: Sept. 8, 2003



Summary of the investigation Singapore

- The patient most likely acquired the infection in BSL-3 laboratory in the Environmental Health Institute where he had worked
- Inappropriate laboratory procedures and a cross contamination of West Nile virus samples with SARS-CoV in the laboratory led to the infection of the doctoral student
- The results of the genome sequencings on the laboratory strain of SARS-CoV and that of the patient's were found to be closely related
- No evidence could be found of any other source of infection
- There is no evidence of secondary transmission case



Assessment of BSL-3,2 Laboratories in Singapore

Other laboratories in Singapore were assessed and recommendations were given regarding the construction of the facilities and laboratory management

1. Environmental Health Institute
2. Singapore General Hospital
3. National University of Singapore
4. Defense Science Organization



Laboratory-Acquired Case of SARS Taiwan (China), Dec. 2003

- Patient: 44-year-old male lab. scientist
- Place of infection: BSL-4 lab., Institute of Preventative Medicine, National Defense Medical Center
- Onset of illness: Dec. 11, 2003
- Hospitalization: Dec. 16, 2003
- Confirmed day: Dec. 17, 2003



Summary of the investigation Taiwan (China)

- He was working on SARS-CoV experiments using a BSL-4 facility at the IPM-NDMC
- He found a **spillage of material** in the transportation chamber and disinfected it with 70% ethanol and cleaned it manually
- **The environment specimens collected from the handle of an alcohol spray bottle from the transportation chamber and the switch panel of the cabinet yielded positive results for SARS-CoV**
- Isolated event : no secondary transmission



Assessment of BSL-3,2 Laboratories in Taiwan (China)



1. Institute of Preventative Medicine, National Defense Medical Center
2. Centers for Disease Control Taiwan, Taipei Laboratories
3. NUT, Chang Gung Memorial Hospital, Taipei
4. Animal Health Research Institute, Taipei
5. National Cheng Kung University Virology Laboratory
6. Kaohsiung Medical Center, Chang Gung Memorial



Laboratory-Acquired SARS Outbreak in China March 2004

- From March to April 2004, an outbreak of SARS involved two verified chains of SARS-CoV transmission (9 individuals) occurred in Beijing and Anhui Province, linked to the National Institute of Virology, China CDC
- The source of the outbreak is most probably failed or incomplete inactivation of SARS-CoV (cold inactivation)
- There have been three generations resulting in 9 cases
- Serological analysis on the laboratory staff revealed three more seroconverted cases and one of them is most likely to have been infected early in Feb. 2004



Laboratory-Acquired SARS Outbreak in China March 2004

- A (female research student) 25 March

2nd

→ B (A's mother) → death

→ C (nurse attending A)

3rd

→ D (C's mother)

→ E (C's aunt)

→ F (C's father)

→ G (retired doctor sharing hospital room with C)

→ H (G's daughter-in-law)

- I (male laboratory researcher) 17 April

SARS IgG (+)

J (female laboratory worker in BSL-3 laboratory)

K (female laboratory worker who developed pneumonia)

L (male laboratory worker, A's supervisor)

China CDC



Common problems

- Bad practice in laboratory management
- Poor supervision of less experienced professionals
- A lack of accountability for occupational health and safety
- A lack of biosafety policy
- A lack of biosafety procedures and staff training in biosafety practice
- A lack of internal and external quality assurance



Recommendations

- Need for a legislative basis for Biosafety Standards for laboratories
- Procedures for timely reporting and follow-up of all unusual laboratory incidents should be developed
- Monitor workers health and instruction of countermeasures
- Accreditation and certification of BSL-3 laboratories should be implemented
- Inventory of infectious agent



Increasing number of BSL-3 laboratories

China CDC



NIHE (Viet Nam)



Xiamen CDC



Guiyang CDC



Assessment of BSL-3 Laboratories & Biosafety Training Program in Viet Nam



Biosafety training course in Viet Nam

- Institution: The National Institute of Hygiene and Epidemiology (NIHE) in Hanoi, Viet Nam
- Duration: 16 to 20 August 2004
- Instructors: Dr. Kazuyoshi SUGIYAMA, Chief, Division of Biosafety Control and Research, National Institute of Infectious Control (NIID), Japan

Dr. Nguyen Viet Hung, Head of infection Control Department, Bach Mai Hospital, Hanoi, Viet Nam



Lecture

I. Principle of Biosafety

1. Biohazard/Biosafety
2. Historical background of biosafety
3. Laboratory acquired infection
4. Significance of aerosol/spray factor
5. Principles of biosafety
6. Biosafety level
7. BSL-2-4 laboratories
8. Countermeasure for accident

II. Management system of pathogens in NIID

1. Regulations
2. Laboratory safety management
3. Training and education
4. Relationship to local community (residents)

III. Biosecurity and international tendency of biosafety



Practice and Laboratory Evaluation

Practice of Biosafety

1. Proper use Biological Safety cabinet
2. Disinfection / Disinfectant
3. Transportation of pathogenic agents

Laboratory Evaluation

1. Biological hazard area, BSL-3 laboratory
2. Respiratory virus laboratory
3. Enteric virus laboratory
4. Bacteriology laboratory
5. BSL-1 laboratory



Biosafety Enhancement Training Workshop for Southeast Asia and China

14 to 18 March 2005

sponsored by

Singapore Ministry of foreign Affairs

and the

Canadian International Development Agency (CIDA)

under the auspices of the

Singapore-Canada Third Country Training Programme

to be jointly conducted by

The Public Health Agency of Canada

and

TEMASK Lifesciences Laboratory

WHO Western Pacific Regional Office



Speakers and Participants

- Speakers

Maureen Best

Kenneth Ugwu

Chua TM

Phillipe Dubois

Futoshi Hasebe

- Participants

Brunei MoH 2, MoA 2

Cambodia

China

Indonesia

Lao-PDR

Philippines

Malaysia

Myanmar

Thailand

Vietnam

Singapore



Lecture and Practice

- National Biosafety Strategy
- WHO Biosafety Program and Collaborating Centers
- Asia-Pacific Biosafety Association
- Regional Emerging Disease Intervention Center
- Introduction to Biosafety and Biocontainment
- Design of Laboratory Containment Facilities
- Biological Safety Cabinets
- Certification and Recertification
- Containment Facility
- BSL-3 Tour
- Operational Biosafety Practices
- Disinfection/Decontamination
- Facility Operation and Maintenance
- Animal Facility Design
- Working with Animals in Containment
- Biosecurity
- Risk Assessment for Biohazard
- Transportation of Infectious Materials
- Emergency Response to Biological Incidents
- Biosafety Program Management
- Regional Biosafety Strategy
- Gaps in National Laboratory Capacities
- Establishing a SEAsia Laboratory Network



Who is handling SARS-CoV?



As of 4 April 2005: 1018 (657)

Australia	5	Japan	15
Belgium	3	Netherland	16
Canada	34	Poland	3
China	301	Russia	4
Denmark	1	Singapore	35
France	5	Spain	7
Germany	32	Sweden	2
Greece	1	Switzerland	2
India	4	Taiwan	41
Ireland	1	Thailand	2
Israel	5	UK	16
Italy	6	USA	116




SARS-CoV Related Studies Conducted in the Western Pacific Region

Country	Publications
Australia	5
China	301
Japan	15
Singapore	35
Taiwan (China)	41
Total	397

(397/657 = 60.4%)



SARS-CoV Related Studies in China



China

1. **Chen WQ** Serology
Sun Yat-Sen University, Guangzhou, People's Republic of China
2. **Liu B, Zhou J.** Molecular Biology (modelling)
State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences Beijing 100080, People's Republic of China.
3. **Zhong N, Huang Q, Jin C, Xia B.** Molecular Biology
Beijing Nuclear Magnetic Resonance Center, P.R. China.
4. **Chen Z, Mi L, Xu J, Yu J, Wang X, Jiang J, Xing J, Shang P, Qian A, Li Y, Shaw PX, Wang J, Duan S, Ding J, Fan C, Zhang Y, Yang Y, Yu X, Feng Q, Li B, Yao X, Zhang Z, Li L, Xue X, Zhu P.** Molecular Biology
Department of Cell Biology, the Fourth Military Medical University, Xi'an, China.
5. **Li JN, Xiang KJ, Zhou R, Huang CH,** Molecular Biology (DNA vaccine)
Southern China University of Tropical Agriculture, Danzhou 571737, China.
6. **Yu C, Gui C, Luo H, Chen L, Zhang L, Yu H, Yang S, Jiang W, Shen J, Shen X, Jiang H.** Molecular Biology (modelling)
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School, Chinese Academy of Sciences, Shanghai 201203, China, Shanghai Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Graduate School, Chinese Academy of Sciences, 300 Fenglin Road, Shanghai 200032, China, and School of Pharmacy, East-China University of Science and Technology, Shanghai 200237, China.



Biosafety activity plans in China in 2005

Dr Helene Fredlund: seconded to WHO from
Swedish Institute of Infectious Diseases (SMI)

1. Assessment of biosafety and “Hands on training”
2. Development of laboratory database
3. Training for laboratory managers in biosafety
4. International conference on biosafety



Inventory of Pathogens in Japan

Ministry of Health, Labour and Welfare,
Japan



Questionnaire survey for possession of pathogens in Japan in Dec 2004

Virus		Bacteria	
Small pox	0	Vibrio cholerae	300
SARS-CoV	5	Bacillus dysenteria	543
Ebola virus	0	Salmonella typhi	358
Marburg virus	0	Yersinia pestis	13
Lassa virus	0		
Polio virus	25	Bacteria toxin	
		Cholera toxin	17
		Shigella toxin	6

587 facilities possessed the pathogens among 11,624 investigated facilities



The situation of storage management for pathogens in Japan in Dec 2004

	Inventory location			
	Consolidate	Sectral	Unknown	Others
Medical Institutions	98	93	3	43
Research Institutions	94	77	2	23
Public Institutions	82	16	1	22
Others	21	11	0	1
Total	295	197	6	89



The situation of storage management for pathogens in Japan in Dec 2004

	Administration method			Storage Manual	
	Computerize	Register	Others	Yes	No
Medical Institutions	41	163	30	89	148
Research Institutions	15	167	12	121	75
Public Institutions	7	110	3	70	51
Others	4	27	2	30	3
Total	67	467	47	310	277



WPRO support to countries and reported diseases in 2003 & 2004



* Associate member



Laboratory Assessment in Malaysia and Lao-PDR

Malaysia

- Reference Lab:
 - National Public Health Lab (NPHL)
 - Institute of Medical Research (IMR)
 - Virology Units
 - Bacteriology Units
- Intermediate Lab:
 - Provincial Hospital Lab
 - Ipoh
 - Johor Bahru
 - State Hospital Lab
 - Ipoh
 - Johor Bahru (HSA)
 - Kota Bahru Kelantan
- Peripheral (District Hospital Lab)
 - Mersing Hospital Lab
 - Tumpat Hospital Lab

Lao-PDR

- Reference Lab:
 - National Center for Laboratory and Epidemiology (NCLE)
- Intermediate Lab (Provincial Lab):
 - Savannakhet Hospital Lab
 - Luang Prabang Hospital Lab
 - Luang Namtha Hospital Lab
- Peripheral (District Hospital Lab):
 - Sepol District Hospital



Biosafety situations in BSL-1 & 2



Module-2. Biosafety, Hygiene and Security

Malaysia	Assessment Score (%)
IMR Bact.	76
IMR Virol.	83
NPHL	82
RHL Ipo	81
RHL JB	36
SHL Ipo	74
SHL JB	83
SHL KBK	77
DHP Mersing	91
DHP Tumpat	91


Lao-PDR	Assessment Score (%)
NCLE	54
Savannakhet	69
Luang Prabang	67
Luang Namtha	14
Sepol	28

Future plans

- Assessment of different level of laboratories (peripheral, public health and national reference including BSL-3 laboratories)
- Practical biosafety and biosecurity guidelines for hospital / public health laboratories
- Establishing proper national programme on bio-safety
- Periodical training program for biosafety and good laboratory practice
- Establishing laboratory network



AI outbreaks



Other Biosafety issues

- There are many labs that are not under MOH responsibility, e.g. agriculture, military, environment, commercial labs etc.
- There are double biosafety standards between FAO and WHO as far as HPAI is concerned.

